Pharmacy World and Science

, Volume 21, Issue 3, pp 116–119 | Cite as

Asthma exacerbations during first therapy with long acting β2‐agonists

  • C.M.J.M. Gerrits
  • R.M.C. Herings
  • H.G.M. Leufkens
  • J‐W.J. Lammers


Long acting β2‐agonists (LBA) have become an important therapeutic strategy in the treatment of asthma. There is, however, debate whether LBA increase the risk of asthma exacerbations (AE). We studied whether the risk of AE was increased in patients starting LBA therapy and whether the risk was associated with severity. Patients, aged 5‐49 years, who were firstly prescribed LBA between 1992 and 1995, and who had at least two consecutive prescriptions of LBA, were selected from the PHARMO‐RLS database. The exposure period was the interval between the first and last dispensing of the first exposure episode. The year before the onset was the control period. Single short courses of oral glucocorticosteroids or antibiotics were used as proxy indicators for AE. Severity indicators, assessed in the 6 months before initiation of LBA, were used to classify patients' severity. A total of 788 patients met the inclusion criteria (men: 45.1%, median age: 35). The incidence rate of AE increased significantly (p<0.001) with severity from 1.7 to 2.4 and 1.1 to 2.7 AE per person year in index and control period, respectively. The risk was merely elevated among patients who start LBA therapy without being treated with other anti‐asthma drugs before (RR 1.4, 95% CI 1.0‐2.2). First starters of LBA showed no overall change in incidence of AE when compared with the year before starting treatment. A total of 6.9% of patients used LBA as step‐one therapy. These patients suffer, in contrast to the whole population, a 40% increased risk of having AE. Although this could be due to confounding, we recommend being reluctant to prescribe LBA to patients who have not been treated before with other anti‐asthma drugs.

Asthma Long acting β2‐agonists Pharmacoepidemiology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The British guidelines on asthma management. 1995 Review and position statement Thorax 1997; 52: S1-S21.Google Scholar
  2. 2.
    NIH. Global strategy for asthma management and prevention NHLBI/WHO workshop report. Publication number 95-3659 January 1995.Google Scholar
  3. 3.
    Bone RC. A word of caution regarding a new long-acting bronchodilator. JAMA 1994; 271: 1447-8Google Scholar
  4. 4.
    Bone RC. Another word of caution regarding a new longacting bronchodilator. JAMA 1995; 273: 967-8Google Scholar
  5. 5.
    Aridsson P, Larsson S, Löfdahl CG, Melander B, Svedmyr N, Wåhlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168-73Google Scholar
  6. 6.
    Herings RMC, de Boer A, Stricker BHCh, Leufkens HGM, Porsius AJ. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345(8959): 1195-98Google Scholar
  7. 7.
    Van Ganse E, Van der Linden PD, Leufkens HGM, Herings RMC, Vincken W, Ernst P. Asthma medication and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J 1995; 8: 1856-60 1.Google Scholar
  8. 8.
    Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A et al. Sustained improvement in asthma with longterm use of formoterol fumarate. Ann Allergy 1992; 69(5): 415-20Google Scholar
  9. 9.
    Lundbäck B, Rawlison DW, Palmer JBD. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993; 48: 148-153Google Scholar
  10. 10.
    Douglas NJ, Fitzpatrick MF. Effects of salmeterol on nocturnal asthma. Eur Respir Rev 1991; 4: 293-296Google Scholar
  11. 11.
    Clark CE, Ferguson AD, Siddorn JA. Respiratory arrest in young asthmatics on salmeterol. Respir Med 1993; 87: 227-8Google Scholar
  12. 12.
    Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306(6884): 1034-7Google Scholar
  13. 13.
    Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med. 1997; 156(3 Pt 1): 688-95.Google Scholar
  14. 14.
    Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med. 1994; 150: 1006-11.Google Scholar
  15. 15.
    Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997; 337(20): 1405-11.Google Scholar
  16. 16.
    Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-6.Google Scholar
  17. 17.
    Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC et al. Regular inhaled β agonists in asthma: effects on exacerbation and lung function. Thorax 1993; 48: 134-8.Google Scholar
  18. 18.
    Cockcroft DW, Swysten VA. Funnctional antagonism: tolerance produced by inhaled β2 agonists. Thorax 1996; 51(10): 1051-6Google Scholar
  19. 19.
    Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-9Google Scholar
  20. 20.
    Manolitsas ND, Wang J, Devalia JL, Trigg CJ, McAulay AE, Davies RJ. Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am J Respir Crit Care Med 1995; 151(6): 1925-30Google Scholar
  21. 21.
    Booth H, Fishwick K, Harkawat R, Devereux G, Hendrick DJ, Walters EH. Changes in methacholine induced bronchoconstriction with the long acting β2 agonist salmeterol in mild-to-moderate asthmatic patients. Thorax 1993; 48: 1121-4Google Scholar
  22. 22.
    Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-6Google Scholar
  23. 23.
    Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996; 51: 1100-4Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • C.M.J.M. Gerrits
  • R.M.C. Herings
  • H.G.M. Leufkens
  • J‐W.J. Lammers

There are no affiliations available

Personalised recommendations